1/30/2018
Luis Robayo/AFP/Getty Images

The FDA granted fast-track status to Takeda Pharmaceutical's TAK-426 vaccine for the Zika virus. The vaccine is undergoing testing in 240 adults ages 18 to 49.

Full Story:
Reuters

Related Summaries